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Oral tongue squamous cell carcinoma (OTSCC) is an aggressive cancer associated with poor prognosis. Methods for determining the
aggressiveness of OTSCC from analysis of the primary tumour specimen are thus highly desirable. We investigated whether genomic
instability and proliferative activity (by means of Ki-67 activity) could be of clinical use for prediction of locoregional recurrence in 76
pretreatment OTSCC paraffin samples (stage I, n¼22; stage II, n¼33; stage III, n¼8; stage IV, n¼13). Eleven surgical tumour
specimens were also analysed for remnants of proliferative activity after preoperative radiotherapy. Ninety-seven percent of cases
(n¼72) were characterised as being aneuploid as measured by means of image cytometry. Preoperative radiotherapy (50–68Gy)
resulted in significant reduction of proliferative activity in all patients for which post-treatment biopsies were available
(P-value¼0.001). Proliferative activity was not associated with response to radiation in stage II patients. However, we report a
significant correlation between high proliferation rates and locoregional recurrences in stage I OTSCC patients (P-value¼0.028).
High-proliferative activity is thus related to an elevated risk of recurrence after surgery alone. We therefore conclude that Ki-67
expression level is a potentially useful clinical marker for predicting recurrence in surgically treated stage I OTSCC.
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Oral tongue squamous cell carcinoma (OTSCC) is an aggressive
cancer frequently associated with poor prognosis. Five-year
survival rates remained essentially unchanged over the past 20
years despite advancements in treatment (Myers et al, 2000;
Forastiere et al, 2001; Annertz et al, 2002; Brenner, 2002; Shiboski
et al, 2005). This is partly due to patients dying from metastatic
disease despite being diagnosed at an early stage (Sano and Myers,
2007). Detection of occult metastases is difficult, which is why
prognostic markers in primary diagnostic tumour specimens are
highly desirable.
Treatment failure in OTSCC patients is most frequently due to
local and regional recurrences, with the most important prognostic
indicator being the presence of metastasis in cervical lymph nodes
(Kalnins et al, 1977; Alvi and Johnson, 1996; Ferlito et al, 2001;
Sano and Myers, 2007). Early stage OTSCC patients generally have
a 2-year survival rate of more than 85%, although the survival rate
decreases by approximately 50% with the finding of cervical nodal
metastasis (Sano and Myers, 2007). Some studies have shown a
high rate of occult nodal metastasis (20–40%) despite any
evidence of regional spread on clinical or radiographic evaluation
(Yuen et al, 1999; Ferlito and Rinaldo, 2000). The high rate of
occult metastases is attributable to technological limitations
(Lydiatt et al, 1993; Alvi and Johnson, 1996; Kademani, 2007;
Bilde et al, 2008). As lymph node involvement occurs independent
of tumour size, small primary tumours may have cervical lymph
node metastasis whereas larger tumours do not (Sano and Myers,
2007). Predictive markers indicating a high risk for lymph node
metastasis would have a significant role in determining the
therapeutic strategy for these patients (Sano and Myers, 2007).
Genomic instability and proliferative activity are important
factors for tumour progression and metastatic growth in cancers.
Several studies have shown that aneuploid tumours are more
aggressive than diploid tumours in head and neck cancers (Hogmo
et al, 1994; Rubio Bueno et al, 1998). Proliferative activity, as
determined by expression levels of the Ki-67 nuclear antigen, has
been linked to prognosis and treatment prediction with varying
results in oral cancer, with few studies performed exclusively in
OTSCC (Xie et al, 1999; Pich et al, 2004; Lothaire et al, 2006; Kim
et al, 2007). The use of immunohistochemistry and DNA
cytometry are cost-effective and robust clinical tests. We hereby
investigate whether Ki-67 expression and ploidy measurements
can be of clinical use for prediction of locoregional recurrence
exclusively in primary OTSCC.
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sMATERIALS AND METHODS
Patients
Seventy-six formalin-fixed, paraffin-embedded pretreatment
biopsy specimens with histopathologically confirmed OTSCC,
UICC stages I–IV, treated at the Department of Oto-Rhino-
Laryngology, Karolinska University Hospital (Stockholm, Sweden)
from January 2000 to December 2004 were investigated. Eleven
surgical specimens were obtained from stage II patients following
preoperative radiation, in addition to the biopsy specimens already
collected. All histological samples were reviewed by an experienced
pathologist (GE) who was blinded to clinical outcome. Clinical
information, including age, tumour grading, treatment modality,
treatment response and follow-up according to stage were
retrieved from the medical records. The present study was carried
out with approval from the Research Ethical Review Board in
Stockholm.
The general treatment for OTSCC depended on the UICC
classification stage and patient performance status (Greene et al,
2002). The stage and size of the tumour was determined prior to
treatment plan with CT/MRI, ultrasound-guided fine-needle
aspiration cytology and palpation under general anaesthesia.
A specific treatment plan for each patient was decided at a
conference between head and neck surgeons, oncologists and
pathologists. Standard treatment at Karolinska University Hospital
during the time of study for stage I OTSCC consisted of local
resection alone. Standard treatment for stage II OTSCC included
preoperative radiotherapy against the tumour and ipsilateral neck
nodes followed by hemiglossectomy 4–6 weeks after radiotherapy
treatment was concluded. Deviations in treatment could occur
depending on the growth pattern and radiation response of the
tumour. Patients diagnosed with OTSCC stages III and IV were
treated individually according to their size and spread, with
surgery and/or radiotherapy and/or chemotherapy. Generally
preoperative radiotherapy was given with a total dose of 50–
68Gy, which was a normal preoperative radiotherapy dose for
head and neck cancers in Stockholm. The radiation range varied
depending on the clinical presentation of the patient and growth
pattern of the tumour. After preoperative radiotherapy, surgery
was performed as soon as possible to avoid delay time. The time
between preoperative radiotherapy and surgery, usually 4–6
weeks, depended on the patient’s recovery time for optimal
surgical treatment. Pictorial presentation of treatment and
experimental design is shown in Figure 1.
Evaluation of radiation response was performed by histopatho-
logical examination of the formalin-fixed surgical specimen and
was classified as complete pathological remission (pCR) if no
morphological intact tumour cells were found. Incomplete
pathological remission (non-pCR) was classified when remnant
tumour cells were detected histopathologically.
Ki-67 immunohistochemical staining
Slides used for immunohistochemical staining were cut into 4mm
sections. Two 4mm sections were cut before and after the
immunohistochemical sections for haematoxylin-eosin (HTX)
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Figure 1 Pictorial presentation of specimen accrual, treatment and experimental design. UICC refers to International Union Again Cancer.
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sstaining. The HTX slides were evaluated by our pathologist (FP) to
confirm tumour representativity for the Ki-67 slides. Immuno-
histochemistry of molecular markers for Ki-67 was performed a
week after cutting, using the Benchmark XT system, a product of
Ventana Medical Systems, which automatically prepares and stains
the 4mm Ki-67 slide sections. All 76 slides were placed in the
machine at the same time to avoid any discrepancies in staining.
We used the monoclonal antibody MIB-1 (DAKO, Glostrup,
Denmark). Immunohistochemistry of Ki-67 was performed on 76
tumour tissue sections. Tonsil cancer served as a positive control
for the staining. The Benchmark XT system has an external-
negative control to the primary antibody during each run. Staining
reproducibility was verified by staining five new slides of
previously stained Ki-67 cases for comparison purposes. The
results, according to our pathologist (JL), showed that the slides
were similarly stained and produced the same score as the
previous batch. With standardised staining/analysis techniques,
the results were thus reproducible.
Ki-67 immunohistochemical evaluation
The stained Ki-67 slides were analysed according to their nuclear
staining pattern using the VIAS workstation, a Ventana Image
Analysis System. Using the combined automatic segmentation
tool, four representative tumour areas on the sections were
manually chosen on low power ( 40) magnification and automatic
counting was performed at  400 magnification ( 40 objective).
One pathologist (FP) performed the analysis.
Approximately 1000 cells were evaluated per case, with the given
percentages from 0 to 100, with 0 being no nuclear staining to 100
being total nuclear staining of the cells. The analyses were
performed without prior knowledge of the clinical outcome.
Ki-67 expression comparisons were made by using the percentages
(0–100%) as a continuous variable and by dividing the scores into
two categorical groups. The two categorical groups consisted of
two different cutoff points, with the first at 50 (low: 0–50, high:
51–100), and the second at 32 (low: 0–32, high: 33–100). The first
cutoff value at 50 was chosen as being half the value of the
continuous variable. The second cutoff value at 32 was chosen for
statistical purposes according to a similar study by Davies et al
(2006).
DNA cytometry
Image cytometry was to be performed on 76 pretreatment biopsy
sections (8mm) with tumour representativity confirmed by our
pathologist (GE) with corresponding HTX slides. Four patient
samples were eliminated due to tumour non-representativity. Of
72, 8mm slides were then Feulgen stained to measure the nuclear
DNA content of the tumour cells. The staining, internal
standardisation, and tumour cell selection were based on
previously described methods (Steinbeck et al, 1999). DNA values
were determined in relation to a corresponding control, which
denoted the normal DNA (diploid) content at 2c. The specimens
were divided into two groups by their corresponding histogram.
Histograms with stem lines in the 2c region and no cells exceeding
4c represented diploid tumours. Aneuploid tumours were denoted
by one or more peaks outside the 2c region and a substantial
number of cells with DNA values exceeding the 4c region.
Approximately 100 cells were analysed for each tumour specimen.
Statistical analysis
The data was statistically analysed by means of the SAS version 9.1
software (SAS Institute: Cary, NC, USA). The Mantel–Haenszel
w
2-test (w
2 MH) was used to assess associations between Ki-67
categorical variables and clinicopathologic factors. The Kruskal–
Wallis test was used for continuous variable assessments
between clinicopathologic factors and the immunohistochemical
biomarker. The log-rank test was used to screen for clinical and
immunohistochemical prognostic values. The Kaplan–Meier
survival curves were constructed to compare differences in
survival, using a 60-month cutoff with the Stata/IC10 software.
Survival was calculated from the date of tumour diagnosis until the
time of death from any cause, or in patients who remained alive,
the time of last follow-up (follow-up time varied from 36 to 60
months). All P-values were from a two-sided test with a P-value
o0.05 considered to indicate statistical significance.
RESULTS
Clinicopathologic and immunohistochemical analyses
Baseline patient characteristics were reviewed according to cancer
stages I–IV (Table 1). Fifty percent of the patients were dead
following a minimum 3-year follow-up since cancer diagnosis, with
a median survival time of 22 months (mean: 27 months, range:
3–60 months). In early OTSCC, 23 out of 55 patients in stages I
and II had a recurrence. Out of which, 22 patients had locoregional
recurrences (4 local recurrences and 18 regional recurrences) and 1
patient had a systemic recurrence. In stage I OTSCC, one patient
received post-operative radiotherapy.
Ki-67 nuclear staining could be detected in all 76 formalin-fixed
biopsy specimens and 11 formalin-fixed surgical tumour samples
analysed. Ki-67 expression did not correlate to stage (P-value¼
0.181). In addition, statistical analyses were made between Ki-67,
DNA content, and resection status, with no correlation seen
between the three parameters. The percentage of Ki-67-positive
cells within a tumour sample ranged from 17 to 95% with a median
of 56%. Figure 2A illustrates a low-proliferative tumour and
Figure 2B demonstrates a high-proliferative tumour. The first
Ki-67 categorical division contained 29 samples in the low
percentage group (0–50) and 47 samples in the higher Ki-67
percentage group (51–100). The second Ki-67 categorical division
contained 10 samples in the low percentage group (0–32), and 66
samples in the higher percentage group (33–100).
DNA cytometry analyses
Image cytometric measurements on pretreatment biopsies resulted
in 97% aneuploid and 3% diploid tumours (n¼72). Two stage I
tumours characterised as diploid were alive after follow-up time
ended. One patient with a diploid tumour had no recurrence
whereas the second patient had a secondary primary tumour
(Ki-67-positive cells: 49 and 32%, respectively). The fact that the
majority of cancers were aneuploid, prevented a meaningful
statistical analysis of a potential association between genomic
instability and recurrence.
Prediction of locoregional recurrences
Ki-67 levels were not associated with locoregional recurrence
in stages II–IV tumours. However, a significant correlation
(P-value¼0.028) was detected between Ki-67 expression in stage
I primary tumours and locoregional recurrences. A higher Ki-67
expression in stage I correlated with a higher number of
locoregional recurrences in two of three assessments (Table 2).
After adjusting for stage and recurrence in a multivariate analysis,
a significant correlation was not detected in Ki-67 levels.
Ki-67 response to radiotherapy
In stage II OTSCC, 27 out of 33 patients underwent preoperative
radiotherapy. Radiotherapy response was measured pathologically
with 7 out of 27 pCR and 20 out of 27 non-pCRs. We could not
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sFigure 2 Immunohistochemical detection in primary pretreatment biopsies of: (A) a low percentage (17%) of Ki-67-positive nuclear staining; (B) a high
percentage (93%) of Ki-67-positive nuclear staining.
Table 1 Patient and tumour characteristics according to stage
Characteristics
Stage I
a
n¼22
Stage II
a
n¼33
Stage III
a
n¼8
Stage IV
a
n¼13
Total
n¼76 (%)
Age at diagnosis (years)
20–39 3 5 1 1 10 (13)
40–59 10 15 4 2 31 (41)
459 9 13 3 10 35 (46)
Gender
Male 9 23 5 7 44 (58)
Female 13 10 3 6 32 (42)
Smoking habit
Smoking 11 17 5 6 39 (51)
Non-smoker 7 12 2 2 23 (30)
No information 4 4 1 5 14 (18)
Histopathologic grade
b
Well differentiated 9 5 1 3 18 (24)
Moderately differentiated 11 22 7 7 47 (62)
Poorly differentiated 2 6 0 3 11 (14)
Preoperative radiation response
pCR 0 7 1 0 8 (11)
Non-pCR 0 20 5 3 28 (37)
Survival
Alive 17 16 2 3 38 (50)
Dead 5 17 6 10 38 (50)
Resection status
R0 22 27 5 4 58 (76)
R1 0 1 0 1 2 (3)
R2 0 0 0 0 0 (0)
No primary surgery 0 5 3 8 16 (21)
Recurrence
Locoregional 9 13 NA NA NA
Systemic 0 1
No recurrence 11 19
Secondary primary 2 0
Ki-67
Mean 48 59 56 60 NA
Range 17–80 18–95 33–87 19–93
Abbreviations: pCR, complete pathological remission; NA, not applicable; non-pCR, incomplete pathological remission; R0, no gross residual disease and negative margins of
resection; R1, residual microscopic disease; R2, residual gross disease.
aTNM stage, tumour stage according to UICC.
bTumour differentiation grade according to WHO
international histologic classification of tumours.
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and non-pCR cases.
Ki-67 expression levels were evaluated before and after radio-
therapy treatment in eleven stage II patients. These patients were
classified as non-responders to radiotherapy. Ki-67 levels
decreased in all eleven patients in comparison to their pretreat-
ment specimens (Table 3).
Survival outcome
The relationship between Ki-67 expression and overall survival was
assessed in stages I–IV. We did not observe any statistical
differences in overall survival between Ki-67 expression and
tumour stage. However, in stage I OTSCC a trend is observed, with
patients exhibiting low Ki-67 expression (Ki-67p32%) tending to
fare better than patients with Ki-67 expression above 32%
(Figure 3A). This trend was not observed in stage II OTSCC for
the same Ki-67 categorical group (0–32 and 33–100), shown in
Figure 3C. In the Ki-67 categorical groups (0–50, 51–100),
differences in overall survival were not detected for either stages
I or II OTSCC (Figure 3B and D).
In stage II, patients treated with preoperative radiotherapy,
three of seven pCR patients died with two of the three patients
having locoregional recurrences. In the non-pCR group, 8 of 20
patients died with 7 showing locoregional recurrences. All patients
who had locoregional recurrences died within approximately 3
years.
DISCUSSION
To identify patients with a high risk for locoregional recurrence,
we investigated Ki-67 expression as a possible marker in OTSCC.
We found an association between high-proliferative activity and an
increased incidence of locoregional recurrences in stage I OTSCC.
We did not observe a relationship between proliferative activity
and radiotherapeutic response; however, we did detect a decreased
Ki-67 expression in residual post-radiotherapy stage II tumours. In
addition, we detected a survival trend in stage I tumours, although
not significant, where patients with a proliferation score below 33
tended to fare better.
The degree of aneuploidy is an independent predictor of
clinical outcome. Studies have shown that patients with highly
aneuploid tumours have reduced disease-free survival times
compared to patients with less unstable tumours (ie breast and
colorectal cancer; Armitage et al, 1985; Hemmer et al, 1990;
Kronenwett et al, 2006). In oral cancers, ploidy studies have
yielded varying degrees of aneuploidy from 50 up to 70%
(Hemmer et al, 1990; Baretton et al, 1995). Our study represented
a large aneuploid OTSCC population (97%), which reflects high
Table 2 KI-67 expression in relation to locoregional recurrences of early oral tongue squamous cell carcinoma stages
Stages Markers Variables Local/regional recurrence No recurrence P-value
1( n¼22) Ki-67 33–100 8/9 (89%) 6/11 (55%) P¼0.104
a
0–32 1/9 (11%) 5/11 (45%)
Ki-67 51–100 7/9 (78%) 3/11 (27%) P¼0.028
a
0–50 2/9 (22%) 8/11 (73%)
Ki-67 Range 32–80 17–71
(continuous) Mean/average 59 40 P¼0.030
a
Median 58 41
2( n¼33) Ki-67 33–100 13/13 (100%) 17/19 (89%) P¼0.265
a
0–32 0/13 (0%) 2/19 (11%)
Ki-67 51–100 10/13 (77%) 11/19 (58%) P¼0.394
a
0–50 3/13 (23%) 8/19 (42%)
Ki-67 Range 43–95 18–93
(continuous) Mean/average 62 56 P¼0.459
a
Median 56.5 59
aw
2 MH test.
Table 3 KI-67 protein expression in pretreatment and post-treatment biopsies in non-pCR stage 2 OTSCC
Age
a Sex Pretreatment biopsy (%) Post-treatment biopsy
b (%) D change Recurrence Survival
58 F 58 27 31 None Alive
33 M 81 18 63 Locoregional Dead
38 F 53 24 29 None Alive
54 F 50 41 9 Locoregional Dead
53 M 43 31 12 Locoregional Dead
32 F 68 60 8 None Alive
58 M 49 35 14 Locoregional Alive
61 M 55 54 1 Locoregional Dead
21 M 58 47 11 Locoregional Dead
57 M 66 28 38 None Alive
75 F 72 53 19 None Alive
P-value P¼0.001
Mean 59 38 21 NA NA
s.d. 11.3 13.9 17.8
aPatients received preoperative radiation (50–68Gy).
bNon-pCR (incomplete pathological remission).
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results could be due to the inclusion of the entire oral cavity for
most studies whereas our study encompasses only OTSCC
material.
High-proliferative activity (450%) is related to an elevated
recurrence risk after surgery in patients with stage I tumours,
making Ki-67 a potentially useful marker for patients in need of
more extensive treatment (ie surgery with more extensive margins,
neck dissection and postoperative radiotherapy). The high rate of
metastasis in stages I and II tumours is in accordance with
previous studies that show a failure rate at 20–40% (Sano and
Myers, 2007). Earlier studies on Ki-67 expression in locoregional
recurring oral cancers revealed conflicting results (Grabenbauer
et al, 2000; Koelbl et al, 2001; Lavertu et al, 2001; Davies et al, 2006;
Wilson et al, 2006). Two studies have suggested that a Ki-67
labelling index of more than 20% was associated with a
significantly worse locoregional control (56%) in oropharyngeal
cancer (Grabenbauer et al, 2000; Wilson et al, 2006). This is in
agreement with our results that found that high-proliferative
activity is associated with an elevated risk for recurrence. The
study by Davies et al (2006), however, showed that a 0–33% Ki-67
expression was associated with a six-times-greater risk of
recurrence at the leading edge of early stage OTSCC. These
apparent contradictory results could be due to Davis collecting all
node-negative OTSCC, which incorporates both stages I and II
tumours. Our findings investigated the relationship between Ki-67
expression and tumours from only stage I OTSCC. In addition, we
used an automatic staining and counting method that decreases
variability and increases objectivity in the analysis of the Ki-67
expression.
Today we lack the means of predicting radiosensitivity outcome
in OTSCC patients, with the variability of radiotherapy response in
patients with tongue cancer disturbingly high. In our study, we
observed a wider range of radiation dosages (50–64Gy), which
was determined according to specific tumour growth and radiation
response. The wider range of radiation dosage may have an effect
on why many patients in our study did not completely respond to
radiotherapy. Patients treated with preoperative radiotherapy
experienced complete pathological remission (8 of 36) although
the majority (28 of 36) responded only incompletely. We were
unable to determine whether the specific time between preopera-
tive radiotherapy and surgery would influence the patient.
However, assuming that any delay in surgery would be harmful
to the patient, preoperative radiotherapy is therefore an unfavour-
able treatment for the patient. Two stage II patients that
completely responded to radiotherapy and surgery presented with
locoregional recurrences a year and a half after diagnosis, making
it possible that micrometastases were present. The knowledge of
micrometastases would have encouraged further treatment.
Several studies have provided evidence that with a higher
proliferative activity, head and neck cancers may respond
significantly better to radiotherapy (Raybaud-Diogene et al,
1997; Grabenbauer et al, 1998; Kropveld et al, 1998; Couture
et al, 2002). Evidence has shown that Ki-67 may be a potential
marker for radiosensitivity in head and neck carcinomas when
using a cutoff point at o20 or X20% (Raybaud-Diogene et al,
1997; Grabenbauer et al, 1998; Couture et al, 2002). Koelbl et al
(2001), however, did not find a correlation between Ki-67
expression and radiation response, but an improved local control
in tumours with complete response after radiotherapy (40Gy). The
consistently lower proliferation rate found in resected sections
after preoperative radiotherapy as compared to the diagnostic
specimen in all patients could perhaps signify radiotherapy
treatment response in the patient. The varying degrees of change
observed before and after radiotherapy indicate that the individual
response to radiotherapy varies and most certainly depends on
many different factors and is difficult to predict. Our study, which
was performed exclusively on OTSCC, corroborated this inter-
60 40 20
Analysis time (months) Analysis time (months)
0 60 40 20 0
0.00
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
1.00
P-value=0.930
P-value=0.952 P-value=0.137
P-value=0.570
Ki-67 scores: 15–100 Ki-67 scores: 0–50
n=11 (0–50)
n=2 (0–32)
n=31 (33–100)
n=22 (51–100)
n=10 (51–100) n=12 (0–50)
n=7 (0–32)
n=15 (33–100)
Ki-67 scores: 51–100 Ki-67 scores: 0–50 Ki-67 scores: 33–100 Ki-67 scores: 0–32
Ki-67 scores: 33–100 Ki-67 scores: 0–32
60 40 20 0
Analysis time (months)
60 40 20 0
Analysis time (months)
0.00
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
1.00
Figure 3 Kaplan–Meier survival estimates in relation to (A) Ki-67-expression variables (0–32, 33–100) in stage I oral tongue squamous cell carcinoma
(OTSCC); (B) Ki-67-expression variables (0–50, 51–100) in stage I OTSCC; (C) Ki-67-expression variables (0–32, 33–100) in stage II OTSCC; (D) Ki-67-
expression variables (0–50, 51–100) in stage II OTSCC.
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predicting radiosensitivity in OTSCC patients.
When assessing overall survival in OTSCC patients, it is
important to consider the impact of tumour stage. Previous
studies in many different types of cancers have shown that tumour
size and patient survival are correlated (Sargeran et al, 2007; Kim
et al, 2008). In this study, we therefore examined whether Ki-67
expression by stage impacts overall survival in OTSCC. Our results
indicated that, although not significant, stage I patients with a
lower percentage (0–32%) of Ki-67 positively stained cells had a
better overall survival. Ki-67 expression did not correlate with
overall survival in any other stage, possibly because Ki-67
expression below 33% was generally observed in only stage I
OTSCC. Other studies in oral cancer investigating the correlation
between Ki-67 expression and overall survival in patients found
conflicting results although several studies confirmed that a lower
Ki-67 expression exhibited better patient survival (Gonzalez-Moles
et al, 1996; Piffko et al, 1996; Stoll et al, 2000; Myoung et al, 2006;
Kim et al, 2007). One study by Kim et al (2007) observed a
significantly longer patient survival when Ki-67 expression was
below 10% in OTSCC patients. As we did not have many OTSCC
patients with a Ki-67 expression below 10%, we were unable to
corroborate the significance in overall survival at this threshold. In
addition, most studies investigating the correlation between Ki-67
expression and patient overall survival examined the entire oral
cavity and not OTSCC as a separate entity, which complicates
direct comparison. A more favourable prognosis has been seen in
studies assessing overall survival in patients with complete
pathologically response after radiotherapy, although this was not
seen in our study (Brun et al, 2001; Onizawa et al, 2006).
Most studies investigating the clinical value of markers include
tumours from all sub-sites of head and neck cancers. As for
instance, tonsillar cancer and OTSCC show large biological
differences, in terms of radiosensitivity and prognosis, we advocate
the importance of investigating the sub-sites separately. Even base
of tongue cancer and OTSCC cases ought to be separated because
base of tongue cancer show more similarities to tonsillar cancer
than OTSCC, ie HPV positivity (Dahlgren et al, 2004). This is our
reason for focusing specifically on OTSCC.
In stage I OTSCC, a correlation between Ki-67 expression and
survival was seen in scores below 33, however that correlation was
not seen once the categorical cutoff was at 0–50. In comparison, a
correlation between Ki-67 expression and locoregional recurrence
was seen in the higher categorical cutoff (0–50 vs 51–100) but not
in the lower categorical cutoff (0–32 vs 33–100). Due to
inconsistent findings in previous publications, correlations
between Ki-67 expression and patient characteristics such as
survival and locoregional recurrence remain controversial.
However, although our analysis in stage I OTSCC is based only
on 22 cases, by specifically looking at a specific stage, we attempted
to eliminate any confounding factors that stage may have on Ki-67.
In addition, as our tissue was specific for only OTSCC, we believe
this would eliminate any tissue-specific differences during
interpretation.
In this study, Ki-67 expression was examined by immuno-
histochemistry. Due to the high cost for treatment in oral cancer,
the discovery of a molecular marker using immunohistochemistry
would be the most cost-effective means for treatment selection
(Menzin et al, 2007). This study was limited by our small
population size; however, OTSCC is a sub-site specific cancer with
very few published articles. Methodologically, different approaches
in Ki-67 immunohistochemical evaluation were used, making
comparison difficult due to lack of one standardised assessment
method (Pich et al, 2004; Kim et al, 2007). In addition, a limitation
of the study is the heterogeneity of treatment modalities among the
different stages of OTSCC. In this study, a positive methodological
aspect is the use of the Ventana machines to stain and count the
tumour specimen. This allowed for a more objective quantification
of the Ki-67 immunohistochemical marker. In addition, each slide
was stained with the same antibody batch and evaluated in one
sitting, making comparisons between slides more accurate. Despite
the many negative reports in the literature, proliferative activity
measurement may still be a reliable prognostic factor when studies
are performed with well-standardised methodology.
In summary, we found that OTSCC are genomically unstable
cancers. We found that high Ki-67 expression is correlated with
locoregional recurrence in stage I OTSCC patients, making it a
potential marker for additional therapy in patients. However,
additional studies in a larger cohort of patients are warranted
before Ki-67 can be used in clinical setting.
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